Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) Income from Continuing Operations (2016 - 2025)

Tg Therapeutics (TGTX) has 10 years of Income from Continuing Operations data on record, last reported at 84702000.0 in Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 2607.86% year-over-year to 84702000.0; the TTM value through Dec 2025 reached 339440000.0, up 11135.11%, while the annual FY2025 figure was 339440000.0, 11095.79% up from the prior year.
  • Income from Continuing Operations reached 84702000.0 in Q4 2025 per TGTX's latest filing, down from 390895000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 390895000.0 in Q3 2025 and bottomed at 94026000.0 in Q4 2021.
  • Average Income from Continuing Operations over 5 years is 2882550.0, with a median of 25058500.0 recorded in 2022.
  • The widest YoY moves for Income from Continuing Operations: up 9974.61% in 2025, down 2607.86% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 94026000.0 in 2021, then surged by 196.69% to 90915000.0 in 2022, then tumbled by 114.85% to 13505000.0 in 2023, then soared by 76.84% to 3128000.0 in 2024, then plummeted by 2607.86% to 84702000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 84702000.0 in Q4 2025, 390895000.0 in Q3 2025, and 28187000.0 in Q2 2025.